The Hunt For Early Pancreatic Cancer Diagnostics – Article Example

Genna Rollins wrote the article d ‘The Hunt for Early Pancreatic Cancer Diagnostics’ on first December 2014. It centers on how researchers are making strides towards detecting pancreatic cancer in individuals during the early stages to foster proper management and treatment of the disease. The article is important to public health owing to the fact that it elucidates the limitations and hopes ascribed to current research and how these impact on public health.
Attempts to treat numerous cancers have traditionally overlooked pancreatic cancer that is still among the most lethal cancers. Approximately 46, 000 individuals in the US are diagnosed with this disease annually and almost 40, 000 of them pass on. The pitfall in averting this predicament is associated with the fact that most of the diagnoses occur when the disease has metastasized; mostly for two decades. In spite of extensive research efforts, there hasn’t been a serious biomarker that is specific enough to make it considered seriously as a benchmark for the disease’s screening. The article cites that the carbohydrate antigen that the FDA has cleared for monitoring the progress of pancreatic cancer (CAA) 19-9 is problematic since it is similarly elevated in other diseases like chronic pancreatic, and diabetes and almost 15% of the populace do not produce the glycoprotein.
An interesting revelation in the article is that Dr. Ayumu Taguchi, together with his colleagues at the University of Texas’s cancer center in Houston cited that there are four biomarkers that have proven more responsive that CA 19-9 in the distinction of samples drawn from individuals who are healthy, and those that have pancreatic cysts and acute pancreatitis. Any kind of biomarker ascribe to pancreatic cancer needs to have strong operating characteristics and ought to present high negative and positive predictive values. This article is important since it enlightens us that unless we point out groups that are appropriate for screening, any test’s predictive values will most likely not be adequate enough for population-based screening that is widespread.